Worktoplay,
The same points stuck with me also. This collaboration is so important because it is actually the type of partnership we have been trying to find. It encompasses so much more than trials, and is the actual witnessing of the beginning of how personalized medicine will come to fruition. Forget the Pharm. companies for now. They will beg for forgiveness later on.
I also noticed the emphasis on "evidence based" medicine several times. They don't want to waste "time", money, and the unique opportunity to be the first to take this huge leap. It's got to be proven well and beyond.
Ovanome hasn't been mentioned alot as of recent. But there's a good chance we will find out just how big a part DNAP's first tests had in Moffitt's interest. When I saw it on the circle graph it confirmed what we all had postulated. Score.
I still keep coming back to what the "two big moves" are that will catapult DNAP into the next level. Was it La Jolla & Moffit? Actually, if you don't live on trader time, it could very well be. There is many doors that can be opened thru this collaboration, and not just cancer treatment.
The Smart Card. Thinking back two years ago, some of us talked about a personal card that could be kept and updated with new data that applies to your DNA profile and can be used for ordering drugs, doling out treatment, tagging reaction time and efficiency, prescibing not only the proper personally made medicine, but matching and weighing against all other drugs being ingested and balancing it all out with your profile. It seems simple until you think about all the variables in control. It is HUGE.
Hence, a chip to hold this information and the ability to have it changed at your computer or at the doc's office. Update your card today, we have found more info affecting your specified profile.
So, who can possibly handle such a huge data and software construction on such a high performance chip with the speed that it will need in order to service not only the U.S., but the rest of the planet?
Well, just maybe.....
If I was Frudakis, I might say to Affx & IBM; "we now know what we do works, and we now have to prove it. But there has to be someone who can take this to the masses. We need the hardware and software connected to the patient, and directly as possible.
Life sciences, get down.
I think the word "collaboration" will have new meaning in the next few years. This going to turn out to be a long story for all of us here, and yes, it feels better all the time.
Regards.
